Market open
Aileron Therapeutics Inc./$RNTX
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Aileron Therapeutics Inc.
Rein Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is focused on developing therapies in orphan pulmonary and fibrosis indications, including two Phase 2-ready clinical assets. The company's product candidate includes LTI-03: a peptide for which company conducted a Phase 1b dose-ranging, placebo-controlled safety, tolerability, and pharmacodynamic biomarker activity trial in development for the treatment of Idiopathic Pulmonary Fibrosis; LTI-01: proenzyme that completed a Phase 2a dose-ranging, placebo-controlled trial and a Phase 1b safety, tolerability and proof of mechanism trial in loculated pleural effusion, or LPE, patients, an indication that has no approved drug treatment; and LTI-05 and others.
Ticker
$RNTX
Sector
Trading on
Industry
Biotechnology
Headquarters
Employees
11
ISIN
US00887A2042
Website
RNTX Metrics
BasicAdvanced
$38M
-
-$3.51
2.12
-
Price and volume
Market cap
$38M
Beta
2.12
52-week high
$2.50
52-week low
$1.35
Average daily volume
28K
Financial strength
Current ratio
2.376
Quick ratio
2.238
Management effectiveness
Return on assets (TTM)
-20.89%
Return on equity (TTM)
-82.37%
Valuation
Price to book
3.97
Price to tangible book (TTM)
-0.95
Price to free cash flow (TTM)
-1.384
Growth
Earnings per share change (TTM)
2.47%
3-year earnings per share growth (CAGR)
-15.90%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
FAQs
What’s the current market cap for Aileron Therapeutics Inc. stock?
Aileron Therapeutics Inc. (RNTX) has a market cap of $38M as of May 09, 2025.
What is the P/E ratio for Aileron Therapeutics Inc. stock?
The price to earnings (P/E) ratio for Aileron Therapeutics Inc. (RNTX) stock is 0 as of May 09, 2025.
Does Aileron Therapeutics Inc. stock pay dividends?
No, Aileron Therapeutics Inc. (RNTX) stock does not pay dividends to its shareholders as of May 09, 2025.
When is the next Aileron Therapeutics Inc. dividend payment date?
Aileron Therapeutics Inc. (RNTX) stock does not pay dividends to its shareholders.
What is the beta indicator for Aileron Therapeutics Inc.?
Aileron Therapeutics Inc. (RNTX) has a beta rating of 2.12. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.